Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

Collaboration › Details

Evotec–Leucadia: investor conference, 201606 supply service Evotec AG presents at Jefferies 2016 Global Healthcare Conference NYC

	Period	2015-11-18
	Region	New York City
	Country	United States (USA)
	Predecessor	Evotec–Leucadia: investor conference, 201511 supply service Evotec AG presents at Jefferies 2015 Global Healthcare Conference London
	Successor	Evotec–Leucadia: investor conference, 201611 supply service Evotec AG presents at Jefferies 2016 Global Healthcare Conference London
	Partner, 1st	Evotec AG (FSE: EVT, TecDAX)
	Today	Evotec SE (FSE: EVT, MDA X/TecDAX)
	Group	Evotec (Group)
	Partner, 2nd	Jefferies LLC
	Group	Leucadia (Group)
	Product	Jefferies 2016 Global Healthcare Conference New York
	Product 2	drug discovery services
	Person	Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
	Person 2	Hansen, Gabriele (Evotec 201404 VP Corporate Communications + Investor Relations)

Evotec AG. (6/1/16). "Press Release: Evotec to Present at the Jefferies 2016 Global Healthcare Conference (New York)". Hamburg.

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the Jefferies 2016 Global Healthcare Conference in New York, USA.

Jefferies 2016 Global Healthcare Conference, New York City, NY, USA
} Date: Wednesday, 08 June 2016, 08.00 am EDT (02.00 pm CEST)
} Venue: New York, NY, USA
} Presenter: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

The PDF version and the direct link to the webcast of the presentation will be provided at http://www.evotec.com/.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and with Second Genome in the field of inflammatory diseases. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com